🚨 Tomorrow:
🚨Just Announced: AcuraStem Associate Vice President of Discovery and Early Development, Wen-Hsuan (Wen) Chang will present "Development of an UNC13A Cryptic Exon Skipping Antisense Oligonucleotide as a Treatment For ALS" at NextGen Biomed by Oxford Global in London, March 12-14, 2025. 🔬Learn about the remarkable progress of our iNeuroRx® platform in advancing disease-modifying therapies for ALS and in advancing our UNC13A program. AcuraStem’s best-in-class ALS models are powering the discovery of translatable therapies that promise to modify disease progression. 👥 Wen will be on hand to discuss potential collaborations on iNeuroRx® and our groundbreaking UNC13A and SYF2 antisense oligonucleotide drug candidates. Visit us at acurastem.com to learn more and join our mission.